What are the appropriate rivaroxaban dosing regimens for stroke prevention in non‑valvular atrial fibrillation, treatment of acute deep‑vein thrombosis or pulmonary embolism, and postoperative prophylaxis after hip or knee replacement, taking into account renal function and contraindications?

Rivaroxaban Dosing Regimens

Rivaroxaban dosing must be tailored to the specific indication and renal function, with stroke prevention in atrial fibrillation requiring 20 mg once daily (15 mg if CrCl 15-50 mL/min), VTE treatment starting at 15 mg twice daily for 21 days then 20 mg daily, and postoperative prophylaxis using 10 mg once daily. 1

Stroke Prevention in Non-Valvular Atrial Fibrillation

Standard Dosing

• 20 mg once daily with food for patients with CrCl >50 mL/min 2, 1
• This dose demonstrated non-inferiority to warfarin in the ROCKET-AF trial 2

Renal Impairment Adjustments

• 15 mg once daily with food for CrCl 15-50 mL/min 3, 4, 3, 1
  • This dose reduction was validated in ROCKET-AF subgroup analysis showing comparable efficacy and safety to the 20 mg dose in patients with normal renal function 3
  • Rivaroxaban has approximately 33% renal clearance, making it more suitable than dabigatran (80% renal clearance) for moderate renal impairment 3

Critical Renal Function Considerations

• CrCl 15-29 mL/min: Rivaroxaban is approved but use with extreme caution 3, 1
  • Very limited clinical trial data exists for this range as severe renal insufficiency was an exclusion criterion in ROCKET-AF 3
  • Observe closely and promptly evaluate any signs of bleeding 1
• CrCl <15 mL/min or dialysis: Avoid use—no clinical data available 3, 4, 1

Monitoring Requirements

• Assess renal function at least annually in all patients 5
• More frequent monitoring (every 3-6 months) required for CrCl <60 mL/min 5
• A practical approach: divide CrCl by 10 to determine minimum frequency of testing in months 5
• Reassess during acute illness (infections, heart failure) that may transiently affect renal function 5

Treatment of Acute DVT/PE

Initial Treatment Phase

• 15 mg twice daily with food for 21 days 6, 1
• Food intake is mandatory for 15 mg and 20 mg doses to ensure adequate absorption 1

Maintenance Treatment

• 20 mg once daily with food after the initial 21 days 6, 1
• Continue for remaining treatment duration (typically 3-6 months minimum)

Extended Secondary Prevention

After completing ≥6 months of standard anticoagulation:

• 10 mg once daily (with or without food) for continued VTE prevention 6, 7, 1
• This reduced dose demonstrated efficacy in preventing recurrent VTE with acceptable bleeding risk 7
• Alternative: Continue 20 mg daily if higher thrombotic risk 6

Renal Impairment in VTE Treatment

• CrCl 15-29 mL/min: Observe closely for bleeding; limited clinical data 1
• CrCl <15 mL/min: Avoid use 1
• Discontinue if acute renal failure develops during treatment 1

Postoperative VTE Prophylaxis (Hip/Knee Replacement)

Standard Regimen

• 10 mg once daily (with or without food) 1
• Duration:
  • Hip replacement: 35 days total 1
  • Knee replacement: 12 days total 1
• First dose: 6-10 hours after surgery once hemostasis established 1

Renal Considerations

• CrCl 15-29 mL/min: Use with caution, observe for bleeding 1
• CrCl <15 mL/min: Avoid use 1

Perioperative Management for Elective Surgery

Preoperative Interruption

For patients with normal/mild renal impairment (CrCl ≥50 mL/min):

• Low bleeding risk surgery: Stop 2 days before (skip 1 dose) 8
• High bleeding risk surgery: Stop 3 days before (skip 2 doses) 8

For moderate renal impairment (CrCl 30-50 mL/min):

• Low bleeding risk: Stop 2 days before 8
• High bleeding risk: Stop 3 days before 8

For severe renal impairment (CrCl 15-29 mL/min):

• Low bleeding risk: Stop 3 days before 8
• High bleeding risk: Stop 4 days before 8

Postoperative Resumption

Minor/low bleeding risk procedures:

• Resume full dose 24 hours after surgery 8

Major/high bleeding risk procedures:

• Consider reduced dose (10 mg once daily) for first 2-3 days 8
• Then resume full treatment dose 8
• For high thrombotic risk patients, may use 10 mg once daily starting evening after surgery 8

Contraindications and Critical Warnings

Absolute Contraindications

• Active pathological bleeding 1
• Severe hypersensitivity to rivaroxaban 1
• Moderate to severe hepatic impairment (Child-Pugh B or C) or any hepatic disease with coagulopathy 3, 1

Drug Interactions Requiring Avoidance

• Combined P-gp and strong CYP3A4 inhibitors: Ketoconazole, itraconazole, ritonavir, clarithromycin 3, 1
  • These significantly increase rivaroxaban exposure and bleeding risk
• Combined P-gp and strong CYP3A4 inducers: Rifampin, carbamazepine, phenytoin, St. John's wort 3, 1
  • These decrease rivaroxaban levels and may reduce efficacy

Neuraxial Anesthesia Warning

• High risk of spinal/epidural hematoma with neuraxial anesthesia or spinal puncture 1
• Wait at least 18 hours (young patients) to 26 hours (elderly) after last dose before catheter placement/removal 1
• Do not give next dose until ≥6 hours after catheter removal 1
• If traumatic puncture occurs, delay rivaroxaban for 24 hours 1

Special Populations

Pregnancy

• Use only if potential benefit justifies risk to mother and fetus 1
• Dosing not studied in pregnancy; cannot monitor with standard labs 1
• Promptly evaluate any signs of bleeding 1

Elderly Patients

• No dose adjustment needed based on age alone 5
• However, elderly patients often have reduced renal function requiring dose adjustment 3
• Monitor renal function more frequently 5

High CrCl (>95 mL/min)

• Some concern for decreased efficacy of DOACs in atrial fibrillation patients with very high CrCl 5
• Consider individual thrombotic vs bleeding risk assessment 5

Common Pitfalls to Avoid

1. Food requirement: 15 mg and 20 mg doses MUST be taken with food for adequate absorption; 10 mg dose can be taken without food 1

2. Renal function monitoring: Failure to reassess renal function regularly leads to inappropriate dosing 5

3. Premature discontinuation: Increases thrombotic risk; consider bridging with another anticoagulant if stopping for reasons other than bleeding 1

4. Mixing indications: VTE treatment requires higher maintenance dose (20 mg) than stroke prevention dose used in some PCI trials (15 mg) 6

5. Neuraxial procedures: Inadequate timing of drug interruption/resumption around spinal/epidural procedures risks catastrophic spinal hematoma 1